Kobi Altman - ICL Israel CFO, Executive Vice President
| ICL Stock | ILA 1,674 26.00 1.53% |
President
Mr. Kobi Altman serves as Chief Financial Officer at ICLIsrael Chemicals Ltd. since April 1, 2015. His work experience includes the following roles Director at Dead Sea Works Ltd., Rotem Amfert Negev Ltd., Dead Sea Bromine Company Ltd. and Bromine Compounds Ltd. and Senior Vice President and Chief Financial OfficerGlobal Generics Medicine at Teva Pharmaceuticals Industries Ltd. He holds a Bachelors degree in Accounting and Economics and a Masters degree in Economics, both from Bar Ilan University. He is a Certified Public Accountant. since 2015.
| Age | 52 |
| Tenure | 9 years |
| Phone | (972) 3 684 4427 |
| Web | www.icl-group.com |
ICL Israel Management Efficiency
The company has return on total asset (ROA) of 0.1916 % which means that it generated a profit of $0.1916 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4322 %, meaning that it generated $0.4322 on every $100 dollars invested by stockholders. ICL Israel's management efficiency ratios could be used to measure how well ICL Israel manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Yuval Ramon | Elbit Systems | 57 | |
| Shelly Gordon | Elbit Systems | 58 | |
| Yehoshua Yehuda | Elbit Systems | 55 | |
| Ilan Pacholder | Elbit Systems | 64 | |
| Zeev Gofer | Elbit Systems | 66 | |
| Edgar Maimon | Elbit Systems | 64 | |
| Sven Dethlefs | Teva Pharmaceutical Industries | 54 | |
| Yoram Shmuely | Elbit Systems | 62 | |
| Kevin Mannix | Teva Pharmaceutical Industries | N/A | |
| Eliyahu Kalif | Teva Pharmaceutical Industries | 50 | |
| Gianfranco Nazzi | Teva Pharmaceutical Industries | 50 | |
| Jonathan Ariel | Elbit Systems | 62 | |
| Hafrun Fridriksdottir | Teva Pharmaceutical Industries | 57 | |
| Richard Daniell | Teva Pharmaceutical Industries | 52 | |
| Elad Aharonson | Elbit Systems | 45 | |
| Mark Sabag | Teva Pharmaceutical Industries | 52 | |
| Ran Kril | Elbit Systems | 52 | |
| David Temin | Elbit Systems | 67 | |
| David Stark | Teva Pharmaceutical Industries | 54 | |
| Yehuda Vered | Elbit Systems | 65 | |
| Avi Mizrachi | Elbit Systems | 60 | |
Management Performance
| Return On Equity | 0.43 | |||
| Return On Asset | 0.19 |
ICL Israel Chemicals Leadership Team
Elected by the shareholders, the ICL Israel's board of directors comprises two types of representatives: ICL Israel inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ICL. The board's role is to monitor ICL Israel's management team and ensure that shareholders' interests are well served. ICL Israel's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ICL Israel's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Raviv Zoller, Chief Executive Officer | ||
| Nitzan Moshe, Executive Vice President - Global Operations | ||
| Tzipi OzerArmon, Independent Director | ||
| Lilach GevaHarel, Senior Vice President and Global General Counsel | ||
| Avisar Paz, Director | ||
| Yoav Doppelt, Executive Chairman of the Board | ||
| Ilana Fahima, Executive Vice President ICL Global Human Resources | ||
| Ido Lilian, Executive Vice President-Global Procurement | ||
| Reem Aminoach, Independent Director | ||
| Ruth Ralbag, External Independent Director | ||
| Noam Goldstein, President - Potash Division | ||
| Anantha Desikan, Executive Vice President Chief Innovation & Technology Officer | ||
| Maya Grinfeld, VP Communications | ||
| Aviram Lahav, Chief Officer | ||
| Aya Landman, Company VP | ||
| Ofer Lifshitz, President, ICL Phosphate Solutions Division | ||
| Lior Reitblatt, Independent Director | ||
| Nadav Kaplan, Independent Director | ||
| Kobi Altman, CFO, Executive Vice President | ||
| Anat TalKtalav, President ICL Industrial Products Division | ||
| Eli Amon, Executive Vice President ICL Innovative Ag Solutions Division | ||
| Aviad Kaufman, Director | ||
| Miri Mishor, Senior Vice President - ICL Global Information Technology | ||
| Ovadia Eli, External Director | ||
| Amir Meshulam, Senior Vice President Global Internal Auditor | ||
| Advocate GevaHarel, Exec Counsel | ||
| Elad Aharonson, Pres Solutions | ||
| Sagi Kabla, Director |
ICL Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ICL Israel a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.43 | |||
| Return On Asset | 0.19 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.34 % | |||
| Current Valuation | 43.75 B | |||
| Shares Outstanding | 1.29 B | |||
| Shares Owned By Insiders | 44.90 % | |||
| Shares Owned By Institutions | 25.12 % | |||
| Price To Book | 2.00 X | |||
| Price To Sales | 3.31 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in ICL Stock
When determining whether ICL Israel Chemicals is a strong investment it is important to analyze ICL Israel's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ICL Israel's future performance. For an informed investment choice regarding ICL Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ICL Israel Chemicals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.